Cargando…
Wharton’s Jelly-Derived Mesenchymal Stromal Cells as a Promising Cellular Therapeutic Strategy for the Management of Graft-versus-Host Disease
Allogeneic hematopoietic cell transplantation (allo-HCT), a treatment option in hematologic malignancies and bone marrow failure syndromes, is frequently complicated by Graft-versus-host disease (GVHD). The primary treatment for GVHD involves immune suppression by glucocorticoids. However, patients...
Autores principales: | McGuirk, Joseph P., Smith, J. Robert, Divine, Clint L., Zuniga, Micheal, Weiss, Mark L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491656/ https://www.ncbi.nlm.nih.gov/pubmed/25894816 http://dx.doi.org/10.3390/ph8020196 |
Ejemplares similares
-
Mesenchymal Stromal Cells: What Is the Mechanism in Acute Graft-Versus-Host Disease?
por: Dunavin, Neil, et al.
Publicado: (2017) -
Effects of maternal obesity on Wharton’s Jelly mesenchymal stromal cells
por: Badraiq, Heba, et al.
Publicado: (2017) -
The Immunomodulatory Potential of Wharton's Jelly Mesenchymal Stem/Stromal Cells
por: Vieira Paladino, Fernanda, et al.
Publicado: (2019) -
Wharton’ jelly mesenchymal stromal cell therapy for ischemic brain injury
por: Wu, Kuo-Jen, et al.
Publicado: (2018) -
Concise Review: Wharton's Jelly: The Rich, but Enigmatic, Source of Mesenchymal Stromal Cells
por: Davies, John E., et al.
Publicado: (2017)